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Design, synthesis and biological evaluation of HDAC inhibitors 2411. Introduction
Histone deacetylases (HDACs) have been widely recognized as
promising targets for cancer treatment. The primary activity
of HDACs is to remove acetyl groups from the e-amino
groups of lysine residues in the N-terminal extension of the
core histones, which results in chromatin condensation and
transcriptional repression1. Eighteen mammalian HDACs
have been identiﬁed and categorized into four structural and
functionally distinct classes2. Class I (HDAC1–3 and 8), class
II (HDAC4–7, 9 and 10) and class IV (HDAC11) HDACs
share conserved residues in the catalytic core regions and
require zinc ion for deacetylation, while class III (SIRT1–7)
HDACs are unrelated sirtuin deacetylases and require NADþ
for their enzymatic activity3.
A vast number of HDAC inhibitors are currently under
development and four representative structures are shown in
Fig. 1. Vorinostat (SAHA) and romidepsin (FK228) have been
approved by US FDA for the treatment of relapsed cutaneous
T-cell lymphoma (CTCL)4, and there are at least fourteen
HDAC inhibitors under more than eighty clinical trials5. Most
of the HDAC inhibitors have three common features:
cap group, zinc binding group (ZBG) and hydrophobic
spacer6. The hydroxamic acid moiety has been widely
used as zinc binding group. Although it has strong metal
chelating capability, it displays little isoform selectivity
among class I, II and IV HDACs and might result in the
inhibition of other metallo-enzymes or sequestration of metal
ions. Hydroxamic acids also suffer from metabolic and
pharmacokinetic problems such as rapid glucoronidation
and sulfation7.
Different types of non-hydroxamate functionalities have
been reported, such as benzamides8, electrophilic ketones9,
ketoamides10, phosphonates11, N-formylhydroxylamine12 and
so on. The 2-aminobenzamide derivative MS-275 presents
excellent HDAC inhibitory activity and has been in phase
I/II clinical trials for various solid tumors and hematological
malignancies8,13. Nevertheless, many of the non-hydroxamate
HDAC inhibitors have either reduced potency or metabolic
disadvantages. Thus, there remains a need to develop
HDAC inhibitors with new non-hydroxamate zinc binding
group.H
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Figure 1 Examples of clinicall2. Results and discussion
2.1. Molecular design
X-ray crystal structures of human HDAC83,14,15 and two
bacterial HDAC-like enzymes, namely HDLP from Aquifex
aeolicus (related to class I HDACs)16 and HDAH from
Bordetella/Alcaligenes strain FB188 (related to class IIb
HDACs)17,18 have been resolved in 2000 s. HDAC8, which
shares the same active site and zinc binding residues with
HDAC1–3, was used in our virtual screening. The sequence
homology between HDAC8 and HDAC1 is high with 31%
sequence identity and 53% sequence similarity19. In 2010, a
crystal structure of HDAC2 complexed with a benzamide
inhibitor was solved20. HDAC2, which demonstrates 85.2%
sequence identity with HDAC1, was used as the template
for HDAC1 homology modeling to explicate the biological
results.
We searched the database of NCI2000 (with 238,819
molecules) and MiniMaybridge (with about 2000 molecules)
by pharmacophore-based virtual screening. Based on the
crystal structure of HDAC8/TSA complex (PDB code:
1T64), the pharmacophore model was built manually by
mapping the chemical features on the corresponding func-
tional groups of TSA in its binding conformation (Fig. 2)
using Catalyst as reported in the literature21. Particular spatial
shape was generated based on the binding conformation of
TSA using Catalyst default settings, which merged with
pharmacophore features to form the query model for the ﬁrst
round virtual screening. 847 molecules were selected for the
next round of screening.
Molecular docking program DOCK5.0 was employed for
subsequent screening based on the crystal structure of
HDAC8 (PDB code: 1T64). The protocol was veriﬁed by
docking TSA back into HDAC8. The RMSD between the
docking pose and the binding conformation in the crystal
structure is 0.91 A˚. The small molecules obtained were ranked
according to their scores calculated by the energy scoring
function in DOCK program. The top 300 molecules with best
scores were subjected to drug-likeness analysis. Thirty com-
pounds were ﬁnally chosen as candidate molecules for further
investigation.H
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Figure 2 (a) Structure of Trichostatin A (TSA), a natural histone deacetylase inhibitor and (b) the pharmacophore model based on the
bound conformation of TSA. The location constraints (dots and arrows) represent the ideal relative positions in space for the chemical
functions, and the tolerance spheres (colored spheres) represent relative areas around the location constraints where chemical functions
can still participate in mapping to the pharmacophore.
Figure 3 Design of new HDAC inhibitors by combining the structural features of 17a and MS-275.
Scheme 1 Synthesis route of compounds 5a–e. Reagents and conditions: (a) A THF, 10 1C to rt; B Et3N, DBU, THF, rt, 5060%;
(b) 2,5-Dimethoxyaniline, PyBOP, Et3N, DCM, 3040%.
Hui Lu et al.242Among the 30 candidate molecules, compound 17a, which
is featured by its unique structure, was identiﬁed as a new hit
compound with weak HDAC1 inhibitory activity. Com-
pounds 5a–e were designed by combining the cap group and
spacer of MS-275 derivatives with the zinc binding group of
17a to validate the potential of 2,5-dimethoxybenzamide as
zinc binding group. While compounds 13a and 13b were
designed by integrating the spacer and zinc binding group of
MS-275 with cap group from 17a to examine the feasibility of
4-(2-methoxyphenyl)piperidine as a new cap group. Com-
pounds 17b-e were derivatives of 17a with various substituted
benzamides to explore the effects of different substitutions on
the inhibitory activity against HDACs (as shown in Fig. 3).2.2. Chemistry
The general approach to synthesize compounds 5a–e is outlined
in Scheme 1. Condensation of 3-(hydroxymethyl)pyridine or
substituted phenyl methanol (1) with 4-(aminomethyl)benzoic
acid (3) using 1,10-carbonyldiimidazole (2) gave carboxylic acids
4, which underwent an amide coupling reaction with 2,5-
dimethoxyaniline to afford 5.
The synthetic route of compounds 13a–b is outlined in
Scheme 2. Grignard Reaction of tert-butyl-4-oxopiperidine-1-
carboxylate (6) and 1-bromo-2-methoxybenzene (7), followed by
dehydration and deprotection in 6 N HCl and reduction under
50 psi, gave 4-(2-methoxyphenyl)piperidine hydrochloride (10).
Scheme 2 Synthesis route of compounds 13a and 13b. Reagents and conditions: (a) Mg, I2, dry THF, N2 protected, 40 1C to reﬂux,
56%; (b) 6N HCl, reﬂux, 63%; (c) 10% Pd/C, H2, CH3OH, 50 psi, 78%; (d) Methyl 4-(aminomethyl)benzoate, Et3N, triphosgene, DCM
(for 11a 47%); or methyl 4-formylbenzoate, NaBH4, CH3OH, reﬂux (for 11b 63%); (e) 1 mol/L LiOH, THF, rt, 87% and (f) 1, 2-
Phenylenediamine, BOP, Et3N, DMF, rt, 30%.
Scheme 3 Synthesis route of compounds 17a-e. Reagents and conditions: (a) Et3N, tol/DMF (5:1), reﬂux, 69%; (b) Malonic acid,
piperidine, pyridine, reﬂux, 78%; (c) Substituted aniline, PyBOP, Et3N, DCM, rt (for 17a 32%, 17b 47% and 17c 56%); or (1) Substituted
aniline, PyBOP, Et3N, DCM, rt; (2) TFA/DCM; (3) 10% NaOH (for 17d 23% and 17e 31%).
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triphosgene gave urea 11a. Reductive amination of 10 with
methyl 4-formylbenzoate and NaBH4 provided 11b. The inter-
mediates 11 were hydrolyzed and condensed with 1,2-phenyle-
nediamine to afford amides 13.
The synthesis of compounds 17a–e is presented in Scheme 3.
Nucleophilic aromatic substitution of 4-bromo-3-nitrobenzalde-
hyde (14) with 10, followed by Knoevenagel Reaction produced
intermediate 16. In the last steps, condensation of 16 with different
substituted anilines and successive deprotection led to 17.2.3. Biological evaluation
2.3.1. HDAC1 enzyme inhibition assay
Binding modes of benzamide HDAC inhibitors have been
demonstrated in HDAC2/benzamides complex. The hydrogen
atoms of the ortho-NH2 group are involved in hydrogen bonds
with the side chains of histidines 145 and 146, the nitrogen of the
ortho-NH2 group chelates the zinc, and the carbonyl oxygen
interacts with both the tyrosine side chain hydroxyl and the zinc.
Compounds 5a–e are MS-275 derivatives with 2-aminoben-
zamide replaced by 2,5-dimethoxybenzamide from 17a. Com-
pounds 5a–e were evaluated using an HDAC1 enzyme
inhibition assay and the results were shown in Table 1. As
the oxygen atom is more electronegative than the nitrogen
atom, it might result in weaker coordination with the zinc ion,
and this fact might explain the observation that none of these
compounds showed signiﬁcant HDAC1 inhibitory activities.
The results also implicates that a potent zinc binding group is
crucial for HDAC inhibitory activity.
Compounds 13a and 13b are MS-275 derivatives with 4-(2-
methoxyphenyl)piperidine as the cap group. The percentageinhibition of both compounds is slightly higher than that of
MS-275 (Table 2), which suggests favorable interactions of
4-(2-methoxyphenyl)piperidine with the enzyme.
We further examined 17a derivatives with different sub-
stituted benzamides (Table 3) to investigate the effects of
different substitutions on the inhibition of HDACs. Com-
pound 17b with 20-aminobenzamide showed noticeable
HDAC1 inhibitory activity (35.99% inhibition at the concen-
tration of 50 mmol/L). Replacing the 20-aminobenzamide (17b)
with 2-methoxybenzamide (17c) resulted in decreased inhibi-
tory activity, which is consistent with the above result that the
oxygen atom of methoxyl group might have weaker afﬁnity
with the zinc ion. Introduction of 50-phenyl substituent on the
aniline ring (17d) increased the potency remarkably, while
incorporation of 50-methoxyl substituent (17e) had no effects
on potency. These results supported the recognition that the
phenyl moiety may be optimal for binding in the narrow entry
to the internal cavity of the zinc active site, while methoxyl
group is probably too bulky to ﬁt the internal cavity22–24.2.3.2. Molecular docking
To obtain information on the structural basis of the observed
disparity in HDAC1 inhibitory activities, we docked three
20-aminobenzamide containing compounds MS-275, 13a and
17a into HDAC1 homology model using a validated mole-
cular dock program (GOLD)25,26. The homology model was
constructed as described in the literature19. Independent dock-
ing of MS-275 (89.64% inhibition), 13a (95.36% inhibition)
and 17a (35.99% inhibition) revealed that these compounds
exhibited preferences for different binding modes at the pocket
rim (as shown in Fig. 4). For MS-275 and 13a, pyridine and
4-(2-methoxyphenyl)piperidine interact with Tyr 195 at the
Table 2 Biological activities of MS-275 derivatives 13a and 13b with 4-(2-methoxyphenyl)piperidine as cap group.
Compound Y Clog P % Inhibition
of HDAC1 at
50 mmol/L
Cytotoxicity (IC50, mmol/L)
HCT-116 MCF-7 HUVEC
17a  5.048 25.7670.82 450 450 450
13a CONHCH2 2.677 95.3671.62 1.26 19.0 15.6
13b CH2 3.377 93.9870.33 2.12 18.1 34.7
MS-275  0.822 89.6472.84 1.32 23.76 450
Table 1 Biological activities of MS-275 derivatives 5a–e containing 2,5-dimethoxybenzamide as potential zinc binding group.
Compound R1 X Clog P % Inhibition
of HDAC1
at 50 mmol/L
Cytotoxicity (IC50, mmol/L)
HCT-116 MCF-7 HUVEC
17a   5.048 25.7670.82 450 450 450
5a H N 1.559 21.0771.23 19.43 23.56 450
5b 3-OCH3 C 2.975 25.6372.42 35.13 15.11 12.42
5c 4-OCH3 C 2.975 ND
a 14.67 31.22 450
5d 4-Cl C 3.769 10.9270.98 450 NDa 450
5e 4-Ph C 4.944 16.20712.27 16.83 30.56 450
MS-275   0.822 89.6472.84 1.32 23.76 450
aND : not determined.
Table 3 Biological activities of 17a derivatives with different substituted benzamides as zinc binding groups.
Compound R2 Clog P % Inhibition of
HDAC1 at
50 mmol/L
Cytotoxicity (IC50, mmol/L)
HCT-116 MCF-7 HUVEC
17a 2, 5-CH3O 5.048 25.7670.82 450 450 450
17b 2-NH2 4.311 35.9972.29 2.48 450 450
17c 2-CH3O 5.023 25.7672.63 450 450 450
17d 2-NH2-5-Ph 6.199 47.7970.76 450 450 450
17e 2-NH2-5-CH3O 4.447 30.9270.20 4.94 450 450
MS-275  0.822 89.6472.84 1.32 23.76 450
Figure 4 GOLD docking solutions for MS-275 (blue), 13a (yellow) and 17a (green) at HDAC1; (a) Up view of the surface of HDAC1
near the active site and (b) Side view of the benzamides–HDAC1 interaction.
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structure at the entrance of the active site is not ﬂexible
enough to enable the interaction between 4-(2-methoxyphe-
nyl)piperidine and Tyr 195. This docking result explains the
low potency of compounds 17, and suggests that interaction
between the cap group and the enzyme surface is crucial for
HDAC inhibitory activity and the rigidity of the spacer could
affect potency by deﬁning the orientation of the cap group.
2.3.3. Cytotoxic activity in vitro
All compounds were evaluated for cytotoxicity to human
colon cancer HCT-116 cells, human breast adenocarcinoma
MCF-7 cells and human umbilical vein endothelial cells
(HUVEC) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay. As shown in Table 1,
compounds 5a–e showed modest cytotoxicity to HCT-116 and
MCF-7 cells in concert with their low HDAC1 inhibitory
activities. Compounds 13a and 13b exhibited excellent anti-
proliferative activity to HCT-116 cells. Nevertheless, they
also showed cytotoxicity to HUVEC (Table 2). As shown in
Table 3, compounds 17a and 17e exhibited similar anti-
proliferative activity against HCT-116 cells with MS-275 and
have no cytotoxicity to HUVEC. Though 17d presented the
highest potency against HDAC1 in compounds 17, it showed
no anti-proliferative activity to HCT-116 cells. ClogP values
were calculated using Chemdraw. Compounds 17a, 17c and
17d which showed no anti-proliferative activity to HCT-116
cells all have CLogP values greater than 5.3. Conclusions
In summary, ligand- and structure-based virtual screening was
employed to identify novel non-hydroxamate HDAC inhibi-
tors. Based on the newly identiﬁed hit compound 17a, three
series of compounds were synthesized and evaluated on both
HDAC1 inhibitory activity and cytotoxicity. Binding modes of
representative structures were analyzed using the docking
method. MS-275 derivatives 5a–e with 2,5-dimethoxybenza-
mide as zinc binding group showed weak HDAC1 inhibitory
activities suggesting methoxyl as a poor zinc binding group.
Replacement of pyridine in MS-275 with 4-(2-methoxyphe-
nyl)piperidine increased the potency. Compounds 13a and 13b
presented HDAC1 inhibitory activities and anti-proliferative
activity to HCT-116 cells, but they also showed cytotoxicity to
HUVEC. 17a derivatives exhibited modest HDAC1 inhibitory
activities, which according to the docking analysis was due to
the lack of ﬂexibility precluding the interaction of the cap
group with enzyme surface. Our work provided some insights
to the binding interactions of inhibitors with HDAC and
could facilitate development of novel non-hydroxamate
HDAC inhibitors.4. Experimental
4.1. Chemical synthesis
Melting points were determined on Thomas Hoover appara-
tus. Infrared spectra were acquired on Nicolet Impact 410
spectrophotometer using a KBr ﬁlm. The absorption band is
given in cm1. 1H NMR spectra were recorded on a BrukerACF-300 spectrometer (300 MHz). Chemical shifts are pre-
sented in ppm relative to tetramethylsilane. Mass spectra were
obtained on a Mariner Mass Spectrum, or a GC-2010 mass
spectrometer. Elemental analyses were determined on a Carlo
Erba 1106 elementary analysis apparatus.
4.2. General procedures to prepare amides
Method A: A mixture of benzoic acid (1 eq.), PyBOP (1 eq.)
and triethylamine (1.2 eq.) in dichloromethane was stirred at
room temperature for 15 min. Substituted phenylamine
(1.2 eq.) was then added. The mixture was stirred at room
temperature for 8 h. The solvent was removed under reduced
pressure, and the crude product so-obtained was puriﬁed by
column chromatography.
Method B: A mixture of benzoic acid (1 eq.), BOP (1.2 eq.)
and triethylamine (1.2 eq.) in N,N-dimethylformamide (DMF)
was stirred at room temperature for 10 min. Substituted
phenylamine (1.2 eq.) was then added. The mixture was stirred
at room temperature overnight. Aqueous sat. NH4Cl (15 mL)
was added to the mixture and the crude product was collected
by ﬁltration and puriﬁed by column chromatography.
4.2.1. N-[[4-[[(2,5-dimethoxyphenyl)amino]carbonyl]
phenyl]methyl]-3-pyridinylmethyl ester (5a)
1H NMR (DMSO-d6) d: 3.72 (3H, s), 3.80 (3H, s), 4.29 (2H, d,
J¼6.3 Hz), 5.11 (2H, s), 6.73 (1H, dd, J¼9.0 Hz, J¼3.0 Hz),
7.01(1H, d, J¼9.0 Hz), 7.38–7.44 (3H, m), 7.56 (1H, d,
J¼3.0 Hz), 7.80 (1H, d, J¼7.8 Hz), 7.91 (1H, d, J¼8.1 Hz),
7.99 (1H, t, J¼6.0 Hz), 8.54 (1H, d, J¼4.2 Hz), 8.61 (1H, s),
9.31 (1H, s). MS (ESI) m/z: 422.1 [MþH]þ. IR (KBr) cm1:
3382, 3225, 1721, 1528, 1274, 1043. Anal. Calcd for
C23H23N3O5: C, 66.55; H, 5.50; N, 9.97. Found: C, 66.13;
H, 5.98; N, 9.65.
4.2.2. N-[[4-[[(2,5-dimethoxyphenyl)amino]carbonyl]
phenyl]methyl]-3-methoxyphenylmethyl ester (5b)
1H NMR (DMSO-d6) d: 3.72 (3H, s), 3.75 (3H, s), 3.80 (s, 3H),
4.29 (2H, d, J¼6.3 Hz), 5.04 (2H, s), 6.73 (1H, dd, J¼9.0 Hz,
J¼3.0 Hz), 6.94–6.90 (3H, m), 7.01(1H, d, J¼9.0 Hz), 7.26–
7.32 (1H, m), 7.30 (2H, d, J¼8.1 Hz), 7.56 (1H, d, J¼3.0 Hz),
7.89–7.97 (3H, m), 9.31 (1H, s). MS (ESI) m/z: 451.1 [MþH]þ.
IR (KBr) cm1: 3318, 1687, 1650, 1536, 1273, 1057. Anal.
Calcd for C25H26N2O6: C, 66.65; H, 5.82; N, 6.22. Found: C,
66.46; H, 5.73; N, 6.21.
4.2.3. N-[[4-[[(2,5-dimethoxyphenyl)amino]carbonyl]
phenyl]methyl]-4-methoxyphenylmethyl ester (5c)
1H NMR (DMSO-d6) d: 3.72 (3H, s), 3.75 (3H, s), 3.80 (3H, s),
4.27 (2H, d, J¼9.0 Hz), 4.98 (2H, s), 6.73 (1H, dd, J¼9.0 Hz,
J¼3.0 Hz), 6.93 (2H, d, J¼8.4 Hz), 7.01 (1H, d, J¼9.0 Hz),
7.31 (2H, d, J¼8.4 Hz), 7.38 (2H, d, J¼9.0 Hz), 7.55 (1H, d,
J¼3.0 Hz), 7.83–7.97 (3H, m), 9.30 (1H, s). MS (ESI) m/z:
451.1 [MþH]þ. IR (KBr) cm1: 3345, 2940, 1712, 1650, 1536,
1251. Anal. Calcd for C25H26N2O6: C, 66.65; H, 5.82; N, 6.22.
Found: C, 66.60; H, 6.10; N, 6.14.
4.2.4. 4-chlorobenzyl 4-(2,5-dimethoxyphenylcarbamoyl)
benzylcarbamate (5d)
1H NMR (DMSO-d6) d: 3.72 (3H, s), 3.80 (3H, s), 4.28 (2H, d,
J¼5.7 Hz), 5.10 (2H, s), 6.71–6.74 (1H, m), 7.01 (1H, d,
Hui Lu et al.246J¼9.0 Hz), 7.38–7.56 (6H, m), 7.89–7.99 (3H, m), 9.30 (1H, s).
MS (ESI) m/z: 455.4 [MþH]þ. IR (KBr) cm1: 3340, 1512,
1465, 1300, 1247. Anal. Calcd for C24H23ClN2O5
d 3/2 H2O: C,
659.81; H, 5.44; N, 5.81. Found: C, 59.55; H, 5.76; N, 5.72.4.2.5. N-[[4-[[(2,5-dimethoxyphenyl)amino]carbonyl]
phenyl]methyl]-4-biphenylmethyl ester (5e)
1H NMR (DMSO-d6) d: 3.68 (3H, s), 3.72 (3H, s), 4.29 (2H, d,
J¼6.3 Hz), 5.11 (2H, s), 6.72 (1H, dd, J¼9.0 Hz, J¼3.0 Hz),
7.01 (1H, d, J¼9.0 Hz), 7.34–7.49 (6H, m), 7.55 (1H, d,
J¼3.0 Hz), 7.67 (4H, d, J¼7.5 Hz), 7.89–7.56 (3H, m), 9.30
(1H, s). MS (ESI) m/z: 497.2 [MþH]þ. IR (KBr) cm1: 3353,
1693, 1530, 1261, 1225, 1046. Anal. Calcd for C30H28N2O5: C,
72.56; H, 5.68; N, 5.64. Found: C, 72.31; H, 5.93; N, 5.63.4.2.6. N-(4-(2-aminophenylcarbamoyl)benzyl)-4-(2-
methoxyphenyl)piperidine-1-carboxamide (13a)
1H NMR (DMSO-d6) d: 1.26–1.68 (2H, m), 1.81–1.85 (2H, m),
2.88–2.97 (2H, m), 3.08–3.16 (1H, m), 3.83 (3H, s), 4.08–4.12
(2H, m), 4.47–4.48 (2H, m), 6.85–6.96 (4H, m), 7.08–7.22 (3H,
m), 7.32–7.39 (3H, m), 7.83 (2H, d, J¼7.8 Hz), 8.13(1H, s).
MS (ESI) m/z: 457.1 [MþH]þ. IR (KBr) cm1: 3287, 2921,
1622, 1550, 1241, 752. Anal. Calcd for C27H30N4O3: C, 70.72;
H, 6.59; N, 12.22. Found: C, 70.82; H, 6.37; N, 12.07.4.2.7. N-(2-aminophenyl)-4-((4-(2-methoxyphenyl)
piperidin-1-yl)methyl)benzamide (13b)
1H NMR (DMSO-d6) d: 1.83–1.92 (4H, m), 3.14 (3H, m),
3.44–3.47 (2H, m), 3.80 (3H, s), 4.42 (2H, br s), 6.60–6.65 (1H,
m), 6.80 (1H, d, J¼7.8 Hz), 6.92–7.00 (3H, m), 7.12–7.26 (3H,
m), 7.66 (2H, d, J¼7.5 Hz), 8.1 (2H, d, J¼7.5 Hz). MS (EI)
m/z: 415 (Mþ). IR (KBr) cm1: 3385, 3020, 1652, 1504, 1455,
1236, 845. Anal. Calcd for C26H29N3O2: C, 75.15; H, 7.03; N,
10.11. Found: C, 75.23; H, 7.28; N, 9.87.4.2.8. (E)-N-(2,5-dimethoxyphenyl)-3-(4-(4-(2-
methoxyphenyl)piperidin-1-yl)-3-nitrophenyl)acrylamide (17a)
1H NMR (DMSO-d6) d: 1.53–1.87 (4H, m), 2.98–3.11 (3H, m),
3.36–3.40 (2H, m), 3.74 (3H, s), 3.77 (3H, s), 3.81 (3H, s), 6.43
(1H, d, J¼15.3 Hz), 6.53 (1H, dd, J¼9.0 Hz, J¼3.0 Hz), 6.75
(1H, d, J¼9.0 Hz), 6.81 (1H, d, J¼8.1 Hz), 6.87 (1H, m), 7.06
(1H, d, J¼8.7 Hz), 7.16 (2H, d, J¼7.5 Hz), 7.52 (1H, dd,
J¼8.7 Hz, J¼2.1 Hz), 7.58 (1H, d, J¼15.3 Hz), 7.90 (1H, s),
7.94 (1H, d, J¼2.1 Hz), 8.19 (1H, d, J¼2.7 Hz). IR (KBr)
cm1: 2955, 2833, 1679, 1650, 1530, 1208, 1019. MS (ESI) m/z:
518.3 [MþH]þ. Anal. Calcd for C29H31N3O6: C, 67.30; H,
6.04; N, 8.12. Found: C, 67.01; H, 6.02; N, 8.43.4.2.9. (E)-N-(2-aminophenyl)-3-(4-(4-(2-methoxyphenyl)
piperidin-1-yl)-3-nitrophenyl)acrylamide (17b)
1H NMR (CDCl3) d: 1.90 (4H, m), 3.04–3.20 (3H, m), 3.41–
3.46 (2H, m), 3.84 (3H, s), 6.52 (1H, d, J¼15.3 Hz), 6.79–6.84
(2H, m), 6.90–6.93 (1H, m), 6.95–6.98 (1H, m), 7.05–7.12 (2H,
m), 7.18–7.24 (2H, m), 7.28–7.31 (1H, m), 7.53–7.66 (3H, m),
7.96 (1H, s). IR (KBr) cm1: 3413, 3365, 1664, 1605, 1525,
1384, 1218. MS (ESI) m/z: 473.2 [MþH]þ. Anal. Calcd for
C27H28N4O4: C, 68.63; H, 5.97; N, 11.86. Found: C, 68.72; H,
5.94; N, 12.09.4.2.10. (E)-N-(2-methoxyphenyl)-3-(4-(4-(2-
methoxyphenyl)piperidin-1-yl)-3-nitrophenyl)acrylamide (17c)
1H NMR (DMSO-d6) d: 1.88–1.93 (4H, m), 3.05–3.16 (3H, m),
3.43–3.47 (2H, m), 3.84 (3H, s), 3.93 (3H, s), 6.51 (1H, d,
J¼15.6 Hz), 6.87–7.14 (6H, m), 7.18–7.26 (2H, m), 7.57–7.68
(2H, m), 7.95–8.02 (2H, m), 8.50 (1H, d, J¼7.4 Hz). IR (KBr)
cm1: 3347, 1676, 1608, 1529, 1458. MS (ESI) m/z: 488.2
[MþH]þ. Anal. Calcd for C28H29N3O5: C, 68.98; H, 6.00; N,
8.62. Found: C, 69.02; H, 6.02; N, 8.57.4.2.11. (E)-N-(4-aminobiphenyl-3-yl)-3-(4-(4-(2-
methoxyphenyl)piperidin-1-yl)-3-nitrophenyl)acrylamide (17d)
1H NMR (DMSO-d6) d: 1.87–1.88 (4H, m), 3.00–3.14 (3H, m),
3.36–3.40 (2H, m), 3.83 (3H, s), 6.51 (1H, d, J¼15.6 Hz),
6.82–7.02 (4H, m), 7.18–7.37 (6H, m), 7.42–7.62 (5H, m),
7.89–7.94 (2H, m). IR (KBr) cm1: 3377, 1608, 1526, 1490,
1237. MS (ESI) m/z: 549.4 [MþH]þ. Anal. Calcd for
C33H32N4O4: C, 72.24; H, 5.88; N, 10.21. Found: C, 72.24;
H, 6.00; N, 10.23.4.2.12. (E)-N-(2-amino-5-methoxyphenyl)-3-(4-(4-(2-
methoxyphenyl)piperidin-1-yl)-3-nitrophenyl)acrylamide (17e)
1H NMR (DMSO-d6) d: 1.83 (4H, m), 2.98–3.14 (3H, m),
3.35–3.39 (2H, m), 3.67 (3H, s), 3.77 (3H, s), 6.44 (1H, d,
J¼15.3 Hz), 6.56–6.59 (1H, m), 6.73 (1H, d, J¼8.7 Hz), 6.81
(1H d, J¼8.1 Hz), 6.88 (1H, t, J¼7.5 Hz), 7.04 (1H d,
J¼8.7 Hz), 7.12–7.19 (3H, m), 7.25 (1H, m), 7.49 (1H, d,
J¼7.8 Hz), 7.58 (1H, d, J¼15.6 Hz), 7.74 (1H, s), 7.90 (1H, s).
IR (KBr) cm1: 2955, 2833, 1679, 1650, 1530, 1208, 1019. MS
(ESI) m/z: 503.2 [MþH]þ. Anal. Calcd for C28H30N4O5: C,
66.92; H, 6.02; N, 11.15. Found: C, 66.47; H, 5.89; N, 11.43.4.3. Biological evaluation
4.3.1. Fluorimetric HDAC1 assay
The HDAC1 ﬂuorescent activity assay was based on the
Fluor de Lys Substrate and Developer combination (BioMol),
carried out according to the supplier’s instructions. First, the
Fluor de Lys Substrate, which comprises an acetylated lysine
side chain, was incubated with puriﬁed recombinant HDAC1
enzymes in the presence or the absence of test compounds.
Deacetylation of the substrate sensitizes the substrate so that,
in the second step, treatment with the Developer produces a
ﬂuorophore. Fluorescence was quantiﬁed with a TECAN
inphinite M200 station.4.3.2. In vitro cytotoxicity assay
All compounds were dissolved in DMSO at a stock concen-
tration of 10 mg/mL, and diluted with fresh medium before
assays. Cell lines were seeded into 96-well ﬂat bottom plates at
density of 6000 cells/well. Twelve hours after seeding, each
compound dilution was added in duplicate and incubation
continued at 37 1C in a humidiﬁed atmosphere containing 5%
CO2. After 72 h, 20 mL MTT at 5 mg/mL in PBS (ﬁlter
sterilized, light protected, and stored at 4 1C) was added to
each well, and after 4 h of incubation at 37 1C, the ﬂuores-
cence was measured at 570 nm using Thermo Multiskan
Spectrum.
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